Study for Monitoring Antimicrobial Resistance Trends (SMART)

Program Objectives

  1. The program supports measures for the prevention of infection along with conservation and appropriate use of all antibiotics, including: Implementation of the WHO’s Global Action Plan, calling for comprehensive stewardship programs and activities that enhance health system capability to use antibiotics appropriately. 
  2. The SMART study is a valuable resource in determining pathogen prevalence and antibiotic susceptibility and continues to provide evidence for regulatory susceptibility breakpoints and clinical decision-making.

Over 200,000 clinical samples have been collected from patients with complicated intra-abdominal infections since 2002. Over 200,000 clinical samples have been collected from patients with complicated intra-abdominal infections since 2002. Copyright MSD

What are the health needs and challenges?

The rise in antimicrobial resistance over the past 10 years has become one of the world’s most pressing public health problems. An estimated 2 million illnesses and 23,000 deaths are thought to be caused by antibiotic resistance in the U.S. each year. Our company’s long-standing commitment to the global fight against infectious disease goes hand-in-hand with a commitment to help slow the rate of emergence of potentially deadly resistant organisms.

Description of partnership activities and how they address needs and challenges

The SMART program is one of the world’s largest programs for tracking trends in antimicrobial resistance. Over 200,000 clinical samples have been collected from patients with complicated intra-abdominal infections since 2002 and from patients with complicated urinary tract infections since 2010, and analyzed for their in vitro susceptibility to 12 commonly used antibiotics in different regions of the world to monitor changing trends in antibiotic susceptibility. Currently, 192 hospital sites in 54 countries participate in SMART.

Corresponding principle in Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance

We support measures for the prevention of infection along with conservation and appropriate use of all antibiotics, including: Implementation of the WHO’s Global Action Plan calling for comprehensive stewardship programs and activities that enhance health system capability to use antibiotics appropriately. 

Read full Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance (AMR)

Partnership information

Therapeutic Focus Infectious Diseases

Disease(s) Drug-Resistant Infections (AMR)

Program Type(s) Research & Development - Operations Research

Region(s) East Asia & Pacific, Europe & Central Asia, Latin America & Caribbean, Middle East & North Africa, North America, South Asia, Sub-Saharan Africa

Number of Countries 198

Country(ies) Afghanistan, Albania, Algeria, Andorra, Angola, Antigua and Barbuda, Argentina, Armenia, Australia, Austria, Azerbaijan, Bahamas, Bahrain, Bangladesh, Barbados, Belarus, Belgium, Belize, Benin, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, Brazil, Brunei, Bulgaria, Burkina Faso, Burundi, Cambodia, Cameroon, Canada, Cape Verde, Central African Republic, Chad, Chile, China, Colombia, Comoros, Congo, Cook Islands, Costa Rica, Côte d'Ivoire, Croatia, Cuba, Cyprus, Czech Republic, Democratic Republic of the Congo, Denmark, Djibouti, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Estonia, Ethiopia, Fiji, Finland, France, French Guiana, Gabon, Georgia, Germany, Ghana, Greece, Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, Hong-Kong, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kiribati, Kosovo, Kuwait, Kyrgyzstan, Lao PDR, Latvia, Lebanon, Lesotho, Liberia, Libya, Liechtenstein, Lithuania, Luxembourg, Macedonia, Madagascar, Malawi, Malaysia, Maldives, Mali, Malta, Marshall Islands, Mauritania, Mauritius, Mexico, Micronesia, Moldova, Mongolia, Montenegro, Morocco, Mozambique, Myanmar, Namibia, Nauru, Nepal, Netherlands, New Zealand, Nicaragua, Niger, Nigeria, Niue, North Korea, Norway, Oman, Pakistan, Palau, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Poland, Portugal, Qatar, Romania, Russia, Rwanda, Samoa, Sao Tome and Principe, Saudi Arabia, Senegal, Serbia, Seychelles, Sierra Leone, Singapore, Slovakia, Slovenia, Solomon Islands, Somalia, South Africa, South Korea, South Sudan, Spain, Sri Lanka, St. Kitts and Nevis, St. Lucia, St. Vincent and the Grenadines, Sudan, Suriname, Swaziland, Sweden, Switzerland, Syria, Taiwan, Tajikistan, Tanzania, Thailand, The Gambia, Timor-Leste, Togo, Tonga, Trinidad and Tobago, Tunisia, Turkey, Turkmenistan, Tuvalu, Uganda, Ukraine, United Arab Emirates, United Kingdom, United States of America, Uruguay, Uzbekistan, Vanuatu, Venezuela, Vietnam, West Bank and Gaza, Yemen, Zambia, Zimbabwe

Start Date 2002

More information SMART site

Anticipated completion date Ongoing